Chris Ryan

Chris Ryan joined OncLive in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Articles

Pirtobrutinib Improves Patient-Reported Outcomes in Relapsed/Refractory CLL/SLL

June 16th 2025

PROs were improved with pirtobrutinib among evaluable patient with CLL/SLL treated during the BRUIN CLL-321 trial.

Dr McKay on Data for Olaparib Plus Radium-223 in CRPC With Bone Metastases

June 16th 2025

Rana R. McKay, MD, FASCO, discusses data the combination of olaparib plus radium-223 vs radium-223 monotherapy in castration-resistant prostate cancer.

Dr Krishnan on the Potential Clinical Impact of Trispecific Antibodies in R/R Multiple Myeloma

June 16th 2025

Amrita Krishnan, MD, discusses the potential clinical impact of trispecific antibodies in the management of relapsed/refractory multiple myeloma.

The Expanding Role of AR Inhibition in mHSPC Management: With Alicia Morgans, MD, MPH

June 16th 2025

Alicia Morgans, MD, MPH, details the evolving role of AR inhibitors in the mHSPC setting, including the recent expanded approval for darolutamide for this population.

FDA Grants Orphan Drug Designation to CID-078 for SCLC

June 16th 2025

The FDA has granted orphan drug designation to CID-078 for the treatment of patients with small cell lung cancer.

Liso-Cel Yields Durable Responses in R/R Marginal Zone Lymphoma

June 16th 2025

Liso-cel generated deep and durable responses in relapsed/refractory marginal zone lymphoma.

QOL Data Could Help Support Switch to Camizestrant in HR+ Breast Cancer After Emergence of ESR1 Mutation

June 16th 2025

Hope S. Rugo, MD, breaks down the implications of data from SERENA-6 for the management of emergent ESR1-mutant, HR–positive breast cancer.

ASCO 2025 Showcases Emerging Data on MRD-Guided Therapy, Trispecific Antibodies, and Frontline Bispecifics in Myeloma

June 16th 2025

Amrita Krishnan, MD, discusses key data may shape the evolving treatment landscape of multiple myeloma from ASCO 2025.

Dr Scarfò on Updated Safety Data With BGB-16673 in Relapsed/Refractory CLL/SLL

June 15th 2025

Lydia Scarfò, MD, discusses long-term data with BGB-16673 in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

Dr Dimopoulos on Elranatamab Plus Daratumumab and Lenalidomide in Myeloma

June 15th 2025

Meletios A. Dimopoulos, MD, discusses efficacy and safety findings with elranatamab plus daratumumab and lenalidomide in newly diagnosed multiple myeloma.

Anito-Cel Drives Durable Responses in R/R Multiple Myeloma

June 14th 2025

Anitocabtagene autoleucel yielded an overall response rate of 97% in relapsed/refractory multiple myeloma.

IRAKLIA Data Support Subcutaneous Isatuximab as a SOC Administration Approach in Myeloma

June 14th 2025

The IRAKLIA study examined the use of an innovative on-body injector for isatuximab administration in multiple myeloma.

Dr Curtis on Cyclophosphamide GVHD Prophylaxis in Matched Donor Transplant

June 14th 2025

David Curtis, MBBS, PhD, FRACP, FRCPA, discusses the use of post-transplant cyclophosphamide GVHD prophylaxis in matched donor peripheral blood SCT.

Dr Ku on the Safety Profile of JNJ-90014496 in Relapsed/Refractory LBCL

June 14th 2025

Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, discusses safety and efficacy findings with JNJ-90014496 in relapsed/refractory large B-cell lymphoma.

Dr Mayadev on the Prognostic Value of ctDNA in Locally Advanced Cervical Cancer

June 14th 2025

Jyoti Mayadev, MD, discusses the prognostic and predictive significance of ctDNA in locally advanced cervical cancer.

Olutasidenib Maintenance Generates Durable RFS in IDH1-Mutated AML Following Induction CR/CRi

June 13th 2025

Olutasidenib maintenance led to 83% 4-month RFS rate and 89% 12-month OS rate in IDH1-mutated AML.

Ponatinib Is Associated With Improved Survival in Ph+ ALL With MRD Positivity After Induction

June 13th 2025

A post hoc analysis of the PhALLCON study showed response and survival benefits with imatinib in Ph-positive ALL with MRD negativity after induction.

TT125-802 Demonstrates Potential in Advanced NSCLC and Solid Tumors

June 13th 2025

TT125-802 demonstrated early clinical activity and a favorable safety profile in advanced solid tumors.

FDA Grants Fast Track Designation to Nuvisertib for Myelofibrosis

June 13th 2025

The FDA granted fast track designation to nuvisertib for intermediate- or high-risk myelofibrosis.

FDA Approves Perioperative Pembrolizumab for Resectable, Locally Advanced HNSCC

June 12th 2025

The FDA has approved perioperative pembrolizumab adjuvant radiotherapy in resectable locally advanced HNSCC.